Novo Nordisk (0QIU) Price & Analysis

Compare

72 Followers

0QIU Stock Chart & Stats

kr310.34

kr15.20(2.51%)

At close: Jan 08 4:00 PM EST

kr310.34

kr15.20(2.51%)

Day’s Range― - ―

52-Week Rangekr287.55 - kr800.00

Previous CloseN/A

Volume862.13K

Average Volume (3M)1.26M

Market Cap

kr1.40T

Enterprise Valuekr2.04T

Total Cash (Recent Filing)kr41.55B

Total Debt (Recent Filing)kr118.72B

Price to Earnings (P/E)12.6

Beta1.05

Next Earnings

Feb 04, 2026

EPS Estimate

6.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)4.50

Shares Outstanding3,390,128,000

10 Day Avg. Volume1,037,958

30 Day Avg. Volume1,262,486

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

kr407.60

Price Target Upside31.34% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering11

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsNovo Nordisk's trial for Rybelsus in Alzheimer's could be clinically meaningful even with modest benefits, thanks to its broad safety profile.

Product SafetyNovo Nordisk is proactively engaging with physicians to optimize dosing strategies, which could enhance the safety and tolerability profile of its products.

Regulatory ProgressNovo Nordisk confirmed the filing of the Semaglutide 7.2mg dose in the US, indicating regulatory progress.

Bears Say

Growth ConcernsThe company is not viewed as a 'premium' growth entity anymore, with debates expected around the trading price-to-earnings multiple into the future.

Prescription TrendsThere is a lack of growth in prescription trends for Wegovy and Ozempic, with market pressure anticipated from patent expiry and competitor launches.

Sales GuidanceWithout material one-offs, it seems unlikely that the top-end of the sales guide is achievable, making another guide cut likely.

Novo Nordisk News

GoodRx announces weight loss telemedicine subscription, Novo Nordisk pact

GoodRx (GDRX) announced two major initiatives to make FDA-approved GLP-1 medications more widely available. First, the launch of...

20h ago

NVO

GDRX

LifeMD announces new, lower cash-pay price for GLP-1 medications

LifeMD (LFMD) announced a new, lower cash-pay price for GLP-1 medications, Wegovy and Ozempic, made possible through its...

20h ago

NVO

LFMD

Novo launches introductory self-pay offer for Wegovy, Ozempic for $199 per month

Novo Nordisk (NVO) announced that Wegovy injection 0.25 mg and 0.5 mg and Ozempic are now available at...

20h ago

LLY

Novo Nordisk undercuts Lilly’s obesity drug U.S. cash-pay price, Bloomberg says

Danish drugmaker Novo Nordisk (NVO) announced that introductory doses of blockbuster weight loss drugs Wegovy and Ozempic will...

20h ago

LLY

NVO

Tiger Global buys Netflix, exits Eli Lilly in Q3

Chase Coleman’s Tiger Global disclosed in an SEC filing its holdings as of September 30, 2025. Tiger’s new...

4d ago

Mixed options sentiment in Novo Nordisk with shares down 1.65%

Mixed options sentiment in Novo Nordisk (NVO), with shares down 81c near $48.35. Options volume running well above...

4d ago

NVO

Novo Nordisk price target lowered to DKK 400 from DKK 425 at Berenberg

Berenberg lowered the firm’s price target on Novo Nordisk (NVO) to DKK 400 from DKK 425 and keeps...

4d ago

NVO

Scholar Rock sees third-party facility ready for reinspection by end of year

Scholar Rock (SRRK) said Thursday that it had a Type A meeting with the U.S. FDA. The meeting...

4d ago

NVO

SRRK

Investors plan protest vote against Novo Nordisk board shakeup, Reuters reports

Novo Nordisk (NVO) faces a shareholder backlash as minority investors plan a protest vote against a board overhaul...

5d ago

LLY

NVO

Novo denies partnership with Mangoceuticals on obesity drug, Reuters says

Novo Nordisk (NVO) and Eli Lilly (LLY) do not have a weight-loss drug partnership with telehealth website Mangoceuticals...

5d ago

LLY

NVO

Novo Nordisk Faces Challenges Amid Intensifying Competition and Market Pressures

BMO Capital analyst Evan Seigerman maintained a Hold rating on Novo Nordisk today and set a price target...

13d ago

NVO

Cautious Hold Rating on Novo Nordisk Amid Competitive Pressures and Uncertain Growth Prospects

Analyst Evan Seigerman of BMO Capital reiterated a Hold rating on Novo Nordisk, boosting the price target to...

1M ago

NVO

Cautious Outlook for Novo Nordisk Amid Uncertain Pipeline Outcomes and Growth Challenges

Analyst Sachin Jain of Bank of America Securities maintained a Hold rating on Novo Nordisk, with a price...

2M ago

NVO

Hold Rating for Novo Nordisk Amid Restructuring and Market Challenges

Analyst Sachin Jain of Bank of America Securities maintained a Hold rating on Novo Nordisk, with a price...

2M ago

NVO

0QIU FAQ

What was Novo Nordisk’s price range in the past 12 months?

Novo Nordisk lowest share price was kr287.55 and its highest was kr800.00 in the past 12 months.

What is Novo Nordisk’s market cap?

Novo Nordisk’s market cap is kr1.40T.

When is Novo Nordisk’s upcoming earnings report date?

Novo Nordisk’s upcoming earnings report date is Feb 04, 2026 which is in 78 days.

How were Novo Nordisk’s earnings last quarter?

Novo Nordisk released its earnings results on Nov 05, 2025. The company reported kr4.5 earnings per share for the quarter, missing the consensus estimate of kr4.897 by -kr0.397.

Is Novo Nordisk overvalued?

According to Wall Street analysts Novo Nordisk’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Novo Nordisk pay dividends?

Novo Nordisk does not currently pay dividends.

What is Novo Nordisk’s EPS estimate?

Novo Nordisk’s EPS estimate is 6.01.

How many shares outstanding does Novo Nordisk have?

Novo Nordisk has 3,390,128,000 shares outstanding.

What happened to Novo Nordisk’s price movement after its last earnings report?

Novo Nordisk reported an EPS of kr4.5 in its last earnings report, missing expectations of kr4.897. Following the earnings report the stock price went up 0.379%.

Which hedge fund is a major shareholder of Novo Nordisk?

Currently, no hedge funds are holding shares in GB:0QIU

Company Description

Novo Nordisk

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Nordisk (0QIU) Earnings & Revenues

Historic Earnings Reports

0QIU Stock 12 Month Forecast

Average Price Target

kr407.60

▲(31.34% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"289":"kr289","404":"kr404","519":"kr519","634":"kr634","749":"kr749"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":540,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr540.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":407.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr407.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":290,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr290.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[289,404,519,634,749],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,315.27,332.55692307692306,349.84384615384613,367.1307692307692,384.4176923076923,401.70461538461535,418.9915384615384,436.27846153846156,453.5653846153846,470.8523076923077,488.1392307692307,505.42615384615385,522.7130769230769,{"y":540,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,315.27,322.3723076923077,329.4746153846154,336.5769230769231,343.67923076923074,350.78153846153845,357.88384615384615,364.98615384615385,372.08846153846156,379.19076923076926,386.2930769230769,393.3953846153846,400.4976923076923,{"y":407.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,315.27,313.32615384615383,311.3823076923077,309.4384615384615,307.4946153846154,305.5507692307692,303.60692307692307,301.6630769230769,299.71923076923076,297.7753846153846,295.83153846153846,293.8876923076923,291.94384615384615,{"y":290,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":748.63,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":746.74,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":604.84,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":594.7,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":623.09,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":475.89,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":426.72,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":469.51,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":427.78,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":300.16,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":368.59,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":355.64,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":315.27,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >